Publications
Summary
The Leukemia Department at MD Anderson Cancer Center is committed to research into the biology of MDS and its clinical strategies. A list of front line and subsequent studies can be seen in Figure 3 below. Together with these therapeutic trials, significant effort in the molecular biology of MDS is being studied by several investigators under the umbrella of the NIH funded MDS P01 grant (E. Estey, principal investigator). If you are interested in more information regarding any of the information provided here please do not hesitate to contact Guillermo Garcia-Manero, Chief, Section of MDS or Hagop Kantarjian, Chairman, Department of Leukemia, or any Leukemia physician.
Figure 3
| Protocol | Protocol # | PI |
| Ph I HuM195/rGel | DM98-342 | Cortes |
| Ph I/II Randomized CA vs CI vs CIA | ID03-0181 | Faderl |
| Ph I BAY-43-9006 | 2004-0702 | Cortes |
| Ph l/ll Alimta (Pemetrexed) | 2004-0865 | Kantarjian |
| Ph I SAHA + Idarubicin | 2005-0031 | Garcia-Manero |
| Ph I SNS-595 | 2005-0295 | Kantarjian |
| Ph I/II MK-0457 | 2005-0330 | Cortes |
| Ph I RTA 401 (CDDO) | 2005-0469 | Kantarjian |
| Ph I GX15-070MS | 2005-0584 | Borthakur |
| Ph I SJG-136 | 2005-0607 | Ravandi |
| Ph I SAHA + DAC | 2005-0723 | Issa |
| Ph I Oral Sapacitabine | 2005-0768 | Kantarjian |
| Ph I/II CP-4055 | 2006-0132 | O’Brien |
| Ph I/II AT9283 | 2006-0177 | Kantarjian |
| Ph I FTS | 2006-0201 | Borthakur |
| Ph I Triciribine (TCN-PM, VD-0002) | 2006-0249 | Ravandi |
| Ph I KW-2449 | 2006-0275 | Cortes |